Pfizer
Open Questions
Critical Evidence
Pfizer Q3 revenue $17.2B as COVID annualization drags reported growth negative
The ex-COVID 8 percent and oncology 16 percent print is the first clean read of the base Pfizer actually has.
FDA approves Padcev plus Keytruda for perioperative muscle-invasive bladder cancer
A perioperative label granted six weeks early is the strongest franchise extension on the Seagen assets.
Earnings call: Pfizer cost savings tracking to $4.3B with $900M severance still ahead
$4.3 billion of savings with $1.1 billion already redirected into oncology and obesity is the funding mechanism for everything above.
Pfizer oral GLP-1 shows 11.4% weight loss as phase 3 set for first half of 2027
Eleven point four percent weight loss with no plateau plus a dedicated unit is the platform commitment; the missing price is the open term.
Pfizer granted dosing patent on next-generation CDK4-selective inhibitor through 2043
A dosing patent to 2043 behind a 2027 composition expiry is how the oncology franchise is being defended in the meantime.
Pfizer licenses a trispecific T-cell engager for up to $4.2B, $1.9B of it upfront
$1.9 billion payable today against a $4.2 billion headline is the replacement franchise being bought, and the third external oncology addition of the year.
Journal analysis: phase 2 combination missed its primary endpoint overall and hit it in a 41% subgroup
The phase 3 candidate missed its primary endpoint overall and hit it only in 41 percent of patients, which is both the reason to continue and the ceiling on what it can be worth.
Two filers certify against unexpired Pfizer oncology formulation patents, opening a 30-month clock
Two filers certifying against the 2031 and 2032 formulation patents while leaving the 2043 dosing claims alone starts the clock on the exclusivity the replacements depend on.
Podcast: Pfizer commercial chief declines twice to price the oral GLP-1 and points to 'access'
Declining twice to price the oral GLP-1 and assigning the decision to a unit with its own governance is the whole commercial strategy compressed into one answer.
Evidence Ledger
Every claim, the signal behind it, and the verbatim span inside that signal. This is what makes the dossier checkable rather than assertive.| Date | Publisher | Type | Excerpt | Conf. |
|---|---|---|---|---|
| 2026-10-15 | The Orbital — Metabolic Entry | PODCAST | "Pfizer's chief commercial officer said the company has not set a price for its oral GLP-1 candidate and that access rath…" | 78% |
| 2026-10-15 | Reuters — Healthcare | NEWS | "Pfizer said it will license a trispecific T-cell engager from Nirvella Therapeutics for all indications worldwide, for t…" | 85% |
| 2026-10-14 | Earnings Call Transcripts | TRANSCRIPT | "tracking toward $4.3 billion of net savings by year-end against an original target of $4.0 billion" | 88% |
| 2026-10-14 | FDA — Oncology Approvals | FDA | "approved an expanded indication for Padcev, known generically as enfortumab vedotin, in combination with Keytruda for th…" | 87% |
| 2026-10-14 | Reuters — Healthcare | NEWS | "revenue of $17.2 billion, down 3 percent year over year, as sales of its COVID-19 vaccine and antiviral continued to ann…" | 86% |
| 2026-10-13 | Pfizer Newsroom | PRESS_RELEASE | "produced 11.4 percent mean weight loss at 36 weeks in a phase 2b study of adults with obesity, with no plateau observed …" | 88% |
| 2026-10-12 | The Lancet Oncology — Pfizer-sponsored | ACADEMIC | "found the primary endpoint was missed in the intention-to-treat population, with 71 events reached against a prespecifie…" | 83% |
| 2026-10-09 | USPTO — Pharmaceuticals | PATENT | "granted Pfizer a patent covering methods of administering a next-generation CDK4-selective inhibitor" | 78% |
| 2026-10-07 | Federal Register — ANDA Notices | LITIGATION | "Two generic filers filed abbreviated new drug applications and paragraph certifications challenging two unexpired Pfizer…" | 84% |
Activity
Active Themes
The COVID distortion is in its last year and oncology is being reported through
The savings are buying a metabolic platform, and pricing is the unresolved term
The oncology replacement is being bought with an upfront payment, and the first replacement readout missed
Recent Signals
In a hurry?
Read the one-page briefing, or head back to the feed.